BMG Labtech

JUNE 17, 2024

Protein degradation in the cell Research over many years helped build a comprehensive picture of protein synthesis in the cell. However, knowledge of how proteins are broken down and how degradation contributes to cellular regulation is more recent.

Targeted Protein Degradation 40

Targeted Protein Degradation Regulations Research Science 40

Drug Hunter

JUNE 25, 2023

This edition includes Maze’s glycogen synthase 1 (GYS1) inhibitors that were recently licensed to Sanofi, allosteric androgen receptor (AR) modulators that may be of interest to targeted protein degradation researchers, and brain-penetrant HER2 and ROCK2 inhibitors.

Targeted Protein Degradation 130

Targeted Protein Degradation Computational Chemistry Trials Licensing 130

Sygnature Discovery

SEPTEMBER 25, 2023

Sygnature Discovery identifies potent SHP2 degrader compounds using its proprietary targeted protein degrader platform, CHARMED, in collaboration with Japanese specialty chemical company, UBE Corporation. Its staff of over 1,000, which includes 900 scientists, partners with global pharma, biotech and NFP organisations.

Targeted Protein Degradation 52

Targeted Protein Degradation Small Molecule Science Disease 52

Broad Institute

FEBRUARY 27, 2024

CBTS Supergroup Meetings By Rose Circeo February 27, 2024 Breadcrumb Home Chembio-Therapeutics CBTS Supergroup Meetings Regular program meetings draw participants from many research communities to share cutting-edge research and brainstorm new project ideas in a wide variety of fields relevant to chemical biology and therapeutics science.

Targeted Protein Degradation 52

Targeted Protein Degradation DNA Engineering Science 52

Drug Target Review

JULY 23, 2024

Shortly after finishing my studies, I landed my first job in industry working on cell biology research for several disease indications. At the time, research and leadership roles in biotech/pharma industry were predominately held by men and there were not as many opportunities for career development and mentorship from women leaders.

Small Molecule 116

Small Molecule Targeted Protein Degradation Science Disease 116

BMG Labtech

APRIL 16, 2024

Promising future Molecular glues offer exciting opportunities for targeted protein degradation and new ways to reach some of the estimated 85% of undruggable targets in the proteome. 2 Close cousins Both molecular glues and PROteolysis TArgeting Chimeras ( PROTACs ) are targeted-protein degraders.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Drug Development Disease 40

Drug Target Review

OCTOBER 4, 2023

The research community pressed on, turning to novel compounds that were substantially more potent than those used in the first generation. Associating immunomodulatory and cytotoxic payloads on the same ADC could also amplify the therapeutic effect of cytotoxic payloads harnessing the power of the immune system to target tumour cells.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

The Pharma Data

SEPTEMBER 25, 2020

ICR and Cancer Research UK spinout closes Series B financing. Monte Rosa Therapeutics has raised $96m in Series B financing to support further develop of its pipeline of small-molecule protein degraders. Earlier this year, Monte Rosa announced that it had raised an initial £32.5m

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Clinical Development Disease 40

The Pharma Data

DECEMBER 21, 2020

Targeted protein degradation (TPD) is an approach whereby the body’s natural process for degrading proteins is diverted using small molecule drugs to eliminate disease-causing proteins. . TOKYO and CAMBRIDGE, England , Dec. No further financial details are disclosed. ” About Sosei Heptares.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

The Pharma Data

JULY 22, 2021

This collaboration has the potential to be transformational, as it combines our leadership in targeted protein degradation with Pfizer’s global capabilities and deep expertise in breast cancer. Chief Scientific Officer for Oncology Research and Development at Pfizer. Chief Executive Officer at Arvinas.

Targeted Protein Degradation 52

Targeted Protein Degradation Therapies Clinical Trials Treatment 52

The Pharma Data

OCTOBER 15, 2020

a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE platform of targeted protein degradation technology, today announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry. “In

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Science Disease 40

Drug Target Review

JULY 5, 2024

14 However, pharma, biotech companies and contract research organisations (CROs) are actively exploring the potential to scale up organoid screening capabilities ( Table 1 ). Her research interest is in the neuroscience and oncology areas using both traditional and targeted protein degradation approaches.

Targeted Protein Degradation 64

Targeted Protein Degradation Drugs Disease FDA Approval 64

The Pharma Data

SEPTEMBER 15, 2020

We are happy to support their scientific efforts as they tackle complex research challenges that potentially address critical unmet medical needs for patients. Our Degradomer® class of targeted protein degraders expands on the Trilomer® concept, allowing highly specific degradation of disease-causing proteins.

Targeted Protein Degradation 52

Targeted Protein Degradation Molecular Biology Small Molecule Science 52

The Pharma Data

JANUARY 31, 2021

In addition to Metrion, these collaborations with Captor Therapeutics in targeted protein degradation and with PharmEnable to access proprietary artificial intelligence-enabled and medicinal chemistry technologies are a key factor to drive our future growth ambitions.” For more information, please visit [link].

Structure Based Drug Design (SBDD) 52

Structure Based Drug Design (SBDD) Targeted Protein Degradation Drugs Disease 52

Elrig

MARCH 22, 2023

Over the two days, we’ll bring together academia, industry, and the vendor community to discuss recent advancements in two ultra-exciting areas of drug discovery and biological research: therapeutic oligonucleotides and chemical biology. Right now, targeted protein degradation is a critical focus topic across both industry and academia.

Targeted Protein Degradation 40

Targeted Protein Degradation Science Disease Laboratories 40

Drug Hunter

AUGUST 21, 2023

The use of in silico and in vitro assays alleviates ethical concerns on extensive animal research in keeping with the three Rs (Replacement, Reduction, Refinement). Researchers replaced the acidic sulfonamide motif with a benzylic pyridine ether, which significantly improved the K p. Figure 14: Optimization of an NMT inhibitor by DNDi.

Drugs 206

Drugs Disease Targeted Protein Degradation Screening Hits 206

Covalent Modifiers

JANUARY 7, 2025

Tomonori Tamura and Itaru Hamachi Accounts of Chemical Research 2025 58 (1), 87-100 DOI: 10.1021/acs.accounts.4c00628 4c00628 Selective chemical modification of endogenous proteins in living systems with synthetic small molecular probes is a central challenge in chemical biology.

Targeted Protein Degradation 147

Targeted Protein Degradation Pharmaceuticals Research Treatment 147

Elrig

MARCH 13, 2025

Target Innovation & Novel Screening Technologies – Forum Round-Up In the rapidly evolving landscape of drug discovery, the identification and validation of novel therapeutic targets are pivotal to expanding the druggable genome and tackling unmet medical needs.

Targeted Protein Degradation 52

Targeted Protein Degradation RNA Drugs Disease 52

LifeSciVC

FEBRUARY 5, 2025

However, in recent years, huge leaps have been made in drug discovery ranging from novel technologies unearthing new techniques for small molecule development to new modalities like targeted protein degradation that are beginning to open the door to a promising wave of transcription factor-directed therapeutic candidates.

Small Molecule 67

Small Molecule Targeted Protein Degradation Regulations Disease 67